August 2010 Briefing - Allergy
Here are what the editors at HealthDay consider to be the most important developments in Allergy for August 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Genetic Basis for Severe Asthma Identified
MONDAY, Aug. 30 (HealthDay News) -- Interleukin-17A (IL-17A) has been identified as a promoter of severe asthma-like symptoms in mice, a finding that may provide a basis for further research into therapeutic treatments for severe asthma in humans, according to research published online Aug. 29 in Nature Immunology.
Aerobic Training for Asthma Shows Psychosocial Benefits
THURSDAY, Aug. 5 (HealthDay News) -- In adults with asthma, an aerobic training program may reduce anxiety, depression, and asthma symptoms and improve health-related quality of life, according to research published in the August issue of Chest.
Researchers Test Three Agents for Hereditary Angioedema
WEDNESDAY, Aug. 4 (HealthDay News) -- Researchers have found C1 inhibitor concentrate, ecallantide (a recombinant plasma kallikrein inhibitor), and icatibant (a selective bradykinin B2 receptor antagonist) effective in the management and relief of symptoms of hereditary angioedema, according to three studies published in the Aug. 5 issue of the New England Journal of Medicine.
Full Text - C1 Inhibitor (subscription or payment may be required)
Full Text - Ecallantide (subscription or payment may be required)
Full Text - Icatibant (subscription or payment may be required)
Editorial (subscription or payment may be required)
Environmental Traits, Mom's Obesity Tied to Type 1 Diabetes
TUESDAY, Aug. 3 (HealthDay News) -- Consistent with the hygiene and overload hypotheses, environmental factors associated with less antigenic exposure in early life and maternal obesity may be associated with risk for type 1 diabetes, according to a study published in the August issue of the Archives of Pediatrics & Adolescent Medicine.
Industry-Funded Clinical Trials Yield More Positive Outcomes
TUESDAY, Aug. 3 (HealthDay News) -- Drug clinical trials supported by industry are more likely to produce favorable results than trials supported by government or nonprofit/nonfederal organizations, and they are less likely to be published within two years of the study being completed, according to research published in the Aug. 3 issue of the Annals of Internal Medicine.
Diet Appears to Influence Gut Bacteria Types
TUESDAY, Aug. 3 (HealthDay News) -- Gut bacteria may be different in children who eat a high-fiber, vegetation-based diet than in those who consume a typically Western, high-fat, high-sugar, low-fiber diet, and the bacteria may play a role in vulnerability to obesity and allergies, according to research published online Aug. 2 in the Proceedings of the National Academy of Sciences.